Dopamine - PharmaKB

Dopamine

Dopamine (dopamine) is a small molecule pharmaceutical. Dopamine was first approved as Dopamine hydrochloride on 1982-01-01. It is used to treat bradycardia, heart block, hypotension, kidney diseases, and low cardiac output amongst others in the USA. The pharmaceutical is active against D(3) dopamine receptor, D(4) dopamine receptor, D(1A) dopamine receptor, D(1B) dopamine receptor, and D(2) dopamine receptor. In addition, it is known to target glucose-dependent insulinotropic receptor, transient receptor potential cation channel subfamily M member 8, and transient receptor potential cation channel subfamily V member 1.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
urogenital diseases	D000091642
cardiovascular diseases	D002318
signs and symptoms pathological conditions	D013568

Trade Name

FDA

EMA

Dopamine (discontinued: Dopamine, Intropin)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Dopamine hydrochloride

Tradename	Company	Number	Date	Products
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER	Baxter	N-019615 RX	1987-03-27	4 products, RLD, RS
DOPAMINE HYDROCHLORIDE	Hospira	N-018132 RX	1982-01-01	4 products, RLD, RS
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER	Hospira	N-018826 RX	1983-09-30	3 products, RLD, RS

Show 11 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
dopamine hci	New Drug Application	2024-02-22
dopamine hci in 5% dextrose	New Drug Application	2024-01-27
dopamine hydrochloride	New Drug Application	2025-12-11
dopamine hydrochloride and dextrose	New Drug Application	2025-12-18
dopamine hydrochloride in dextrose	New Drug Application	2025-11-03
parcopa		2007-11-05
sinemet	New Drug Application	2024-10-24

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
kidney diseases	EFO_0003086	D007674	N08
hypotension	EFO_0005251	D007022	I95
shock	—	D012769	R57.1
low cardiac output	—	D002303	—
bradycardia	—	D001919	R00.1
heart block	—	D006327	I45.89

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

C: Cardiovascular system drugs

— C01: Cardiac therapy drugs

— C01C: Cardiac stimulants excl. cardiac glycosides

— C01CA: Adrenergic and dopaminergic cardiac stimulants

— C01CA04: Dopamine

N: Nervous system drugs

— N04: Anti-parkinson drugs

— N04B: Dopaminergic agents

— N04BC: Dopamine agonists

HCPCS

Code	Description
J1265	Injection, dopamine hcl, 40 mg

Clinical

Clinical Trials

1218 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Parkinson disease	D010300	EFO_0002508	G20	88	100	69	42	149	415
Schizophrenia	D012559	EFO_0000692	F20	10	14	12	7	27	65
Depression	D003863	—	F33.9	6	8	4	14	22	52
Healthy volunteers/patients	—	—	—	28	3	2	4	15	50
Depressive disorder	D003866	EFO_1002014	F32.A	6	9	5	10	16	43
Heart failure	D006333	EFO_0003144	I50	3	5	7	5	19	37
Major depressive disorder	D003865	EFO_0003761	F22	5	6	3	7	10	29
Shock	D012769	—	R57.1	1	8	10	3	12	29
Cocaine-related disorders	D019970	—	F14	8	12	2	1	4	26
Syndrome	D013577	—	—	3	5	3	5	10	23

Show 129 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Parkinsonian disorders	D020734	—	G20.C	2	3	1	—	8	13
Treatment-resistant depressive disorder	D061218	—	—	—	2	1	—	5	8
Lewy body disease	D020961	EFO_0006792	G31.83	2	2	1	—	4	8
Pain	D010146	EFO_0003843	R52	—	5	1	—	1	7
Tourette syndrome	D005879	EFO_0004895	F95.2	2	2	2	—	1	6
Apathy	D057565	—	—	—	2	2	—	2	6
Left ventricular dysfunction	D018487	—	—	—	—	1	—	5	6
Cardiac surgical procedures	D006348	—	—	—	1	2	—	3	6
Shy-drager syndrome	D012791	EFO_1001050	—	1	1	1	—	3	5
Spinal cord injuries	D013119	EFO_1001919	—	3	2	1	—	1	5

Show 68 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Obesity	D009765	EFO_0001073	E66.9	1	2	—	—	14	17
Movement disorders	D009069	EFO_0004280	G25	4	9	—	—	5	14
Neurodegenerative diseases	D019636	EFO_0005772	G31.9	3	8	—	—	6	14
Hypertension	D006973	EFO_0000537	I10	2	2	—	—	9	13
Substance-related disorders	D019966	EFO_0003890	F13	1	2	—	—	7	10
Brain diseases	D001927	—	G93.40	3	6	—	—	3	9
Disease progression	D018450	—	—	2	1	—	—	3	6
Glioma	D005910	EFO_0000520	—	2	3	—	—	—	5
Macular degeneration	D008268	EFO_0001365	H35.30	—	5	—	—	—	5
Central nervous system diseases	D002493	—	G96.9	—	5	—	—	—	5

Show 86 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Diabetes mellitus	D003920	EFO_0000400	E08-E13	2	—	—	—	2	4
Angina pectoris	D000787	EFO_0003913	I20	1	—	—	—	2	3
Deep brain stimulation	D046690	—	—	1	—	—	—	2	3
Pheochromocytoma	D010673	—	—	1	—	—	—	1	2
Decision making	D003657	—	—	1	—	—	—	1	2
Psychological stress	D013315	—	—	1	—	—	—	1	2
Hyperglycemia	D006943	—	R73.9	1	—	—	—	1	2
Pharmacogenomic testing	D000071185	—	—	2	—	—	—	—	2
Marijuana abuse	D002189	EFO_0007191	F12	1	—	—	—	1	2
Neoplasms	D009369	—	C80	1	—	—	—	1	2

Show 27 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Insulin resistance	D007333	EFO_0002614	E88.819	—	—	—	—	7	7
Rem sleep behavior disorder	D020187	EFO_0007462	G47.52	—	—	—	—	6	6
Aortic valve stenosis	D001024	EFO_0000266	—	—	—	—	—	5	5
Pathologic constriction	D003251	—	—	—	—	—	—	5	5
Myocardial infarction	D009203	EFO_0000612	I21	—	—	—	—	5	5
Bulimia nervosa	D052018	EFO_0005204	F50.2	—	—	—	—	4	4
Hypersensitivity	D006967	EFO_0003785	T78.40	—	—	—	—	4	4
Ventricular dysfunction	D018754	—	—	—	—	—	—	4	4
Femoral fractures	D005264	—	S72	—	—	—	—	4	4
Infarction	D007238	EFO_0009463	—	—	—	—	—	4	4

Show 172 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Dopamine
INN	dopamine
Description	Dopamine is catechol in which the hydrogen at position 4 is substituted by a 2-aminoethyl group. It has a role as a cardiotonic drug, a beta-adrenergic agonist, a dopaminergic agent, a sympathomimetic agent, a human metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a conjugate base of a dopaminium(1+).
Classification	Small molecule
Drug class	dopaminergics (butopamine type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	NCCc1ccc(O)c(O)c1